BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Becquet L, Abad C, Leclercq M, Miel C, Jean L, Riou G, Couvineau A, Boyer O, Tan YV. Systemic administration of orexin A ameliorates established experimental autoimmune encephalomyelitis by diminishing neuroinflammation. J Neuroinflammation 2019;16:64. [PMID: 30894198 DOI: 10.1186/s12974-019-1447-y] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Couvineau A, Voisin T, Nicole P, Gratio V, Blais A. Orexins: A promising target to digestive cancers, inflammation, obesity and metabolism dysfunctions. World J Gastroenterol 2021; 27(44): 7582-7596 [PMID: 34908800 DOI: 10.3748/wjg.v27.i44.7582] [Reference Citation Analysis]
2 Melzi S, Morel AL, Scoté-Blachon C, Liblau R, Dauvilliers Y, Peyron C. Histamine in murine narcolepsy: What do genetic and immune models tell us? Brain Pathol 2021;:e13027. [PMID: 34672414 DOI: 10.1111/bpa.13027] [Reference Citation Analysis]
3 Berhe DF, Gebre AK, Assefa BT. Orexins role in neurodegenerative diseases: From pathogenesis to treatment. Pharmacol Biochem Behav 2020;194:172929. [PMID: 32315694 DOI: 10.1016/j.pbb.2020.172929] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
4 Erichsen JM, Calva CB, Reagan LP, Fadel JR. Intranasal insulin and orexins to treat age-related cognitive decline. Physiol Behav 2021;234:113370. [PMID: 33621561 DOI: 10.1016/j.physbeh.2021.113370] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
5 La Torre ME, Villano I, Monda M, Messina A, Cibelli G, Valenzano A, Pisanelli D, Panaro MA, Tartaglia N, Ambrosi A, Carotenuto M, Monda V, Messina G, Porro C. Role of Vitamin E and the Orexin System in Neuroprotection. Brain Sci 2021;11:1098. [PMID: 34439717 DOI: 10.3390/brainsci11081098] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Couvineau A, Voisin T, Nicole P, Gratio V, Abad C, Tan YV. Orexins as Novel Therapeutic Targets in Inflammatory and Neurodegenerative Diseases. Front Endocrinol (Lausanne) 2019;10:709. [PMID: 31695678 DOI: 10.3389/fendo.2019.00709] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
7 Mimura LAN, Fraga-Silva TFC, Oliveira LRC, Ishikawa LLW, Borim PA, Machado CM, Júnior JACEH, Fonseca DMD, Sartori A. Preclinical Therapy with Vitamin D3 in Experimental Encephalomyelitis: Efficacy and Comparison with Paricalcitol. Int J Mol Sci 2021;22:1914. [PMID: 33671896 DOI: 10.3390/ijms22041914] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
8 Anderson G, Rodriguez M, Reiter RJ. Multiple Sclerosis: Melatonin, Orexin, and Ceramide Interact with Platelet Activation Coagulation Factors and Gut-Microbiome-Derived Butyrate in the Circadian Dysregulation of Mitochondria in Glia and Immune Cells. Int J Mol Sci 2019;20:E5500. [PMID: 31694154 DOI: 10.3390/ijms20215500] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 6.3] [Reference Citation Analysis]
9 Pallais JP, Kotz CM, Stanojlovic M. Orexin/hypocretinin in multiple sclerosis and experimental autoimmune encephalomyelitis. Neural Regen Res 2020;15:1039-40. [PMID: 31823881 DOI: 10.4103/1673-5374.270310] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
10 Fakhoury M, Salman I, Najjar W, Merhej G, Lawand N. The Lateral Hypothalamus: An Uncharted Territory for Processing Peripheral Neurogenic Inflammation. Front Neurosci 2020;14:101. [PMID: 32116534 DOI: 10.3389/fnins.2020.00101] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
11 Mogavero MP, Silvani A, DelRosso LM, Salemi M, Ferri R. Focus on the Complex Interconnection between Cancer, Narcolepsy and Other Neurodegenerative Diseases: A Possible Case of Orexin-Dependent Inverse Comorbidity. Cancers (Basel) 2021;13:2612. [PMID: 34073579 DOI: 10.3390/cancers13112612] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
12 Wang Q, Cao F, Wu Y. Orexinergic System in Neurodegenerative Diseases. Front Aging Neurosci 2021;13:713201. [PMID: 34483883 DOI: 10.3389/fnagi.2021.713201] [Reference Citation Analysis]
13 Jin K, Lu J, Yu Z, Shen Z, Li H, Mou T, Xu Y, Huang M. Linking peripheral IL-6, IL-1β and hypocretin-1 with cognitive impairment from major depression. J Affect Disord 2020;277:204-11. [PMID: 32829196 DOI: 10.1016/j.jad.2020.08.024] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Alain C, Pascal N, Valérie G, Thierry V. Orexins/Hypocretins and Cancer: A Neuropeptide as Emerging Target. Molecules 2021;26:4849. [PMID: 34443437 DOI: 10.3390/molecules26164849] [Reference Citation Analysis]